-DOCSTART- -X- O
Respiratory -X- _ B-Intervention
viruses -X- _ I-Intervention
including -X- _ O
influenza -X- _ O
have -X- _ O
long -X- _ O
been -X- _ O
appreciated -X- _ O
as -X- _ O
a -X- _ O
cause -X- _ O
of -X- _ O
community -X- _ B-Patient
acquired -X- _ I-Patient
pneumonia -X- _ I-Patient
( -X- _ I-Patient
CAP -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
particularly -X- _ O
among -X- _ O
children -X- _ O
, -X- _ O
people -X- _ O
with -X- _ O
serious -X- _ O
medical -X- _ O
co- -X- _ O
morbidities -X- _ O
and -X- _ O
military -X- _ O
recruits. -X- _ O
They -X- _ O
are -X- _ O
increasingly -X- _ O
recognized -X- _ O
as -X- _ O
a -X- _ O
cause -X- _ O
of -X- _ O
CAP -X- _ O
among -X- _ O
adults -X- _ O
, -X- _ O
particularly -X- _ O
older -X- _ O
adults. -X- _ O
Polymerase -X- _ O
chain -X- _ O
reaction-based -X- _ O
testing -X- _ O
has -X- _ O
allowed -X- _ O
detection -X- _ O
of -X- _ O
newer -X- _ O
agents -X- _ O
( -X- _ O
e.g. -X- _ O
human -X- _ B-Intervention
metapneumovirus -X- _ I-Intervention
, -X- _ I-Intervention
coronavirus -X- _ I-Intervention
HKU1 -X- _ I-Intervention
and -X- _ I-Intervention
NL63 -X- _ I-Intervention
) -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
improved -X- _ O
the -X- _ O
ability -X- _ O
to -X- _ O
detect -X- _ O
“old” -X- _ O
viral -X- _ O
infections -X- _ O
such -X- _ O
as -X- _ O
influenza -X- _ B-Intervention
virus -X- _ I-Intervention
and -X- _ I-Intervention
rhinovirus. -X- _ I-Intervention
When -X- _ O
PCR -X- _ O
is -X- _ O
used -X- _ O
, -X- _ O
viruses -X- _ B-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
45–75 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
children -X- _ I-Outcome
and -X- _ I-Outcome
15–54 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
adults -X- _ I-Outcome
with -X- _ I-Outcome
CAP. -X- _ I-Outcome
Co- -X- _ B-Outcome
infection -X- _ I-Outcome
with -X- _ I-Outcome
viruses -X- _ I-Outcome
and -X- _ I-Outcome
bacteria -X- _ I-Outcome
is -X- _ I-Outcome
common -X- _ I-Outcome
and -X- _ O
it -X- _ O
remains -X- _ O
challenging -X- _ O
to -X- _ O
determine -X- _ O
which -X- _ O
patients -X- _ O
have -X- _ O
only -X- _ O
viral -X- _ O
infection -X- _ O
as -X- _ O
the -X- _ O
cause -X- _ O
of -X- _ O
CAP. -X- _ O
Treatment -X- _ O
for -X- _ O
influenza -X- _ B-Intervention
with -X- _ O
neuraminidase -X- _ O
inhibitors -X- _ O
should -X- _ O
be -X- _ O
started -X- _ O
promptly -X- _ O
for -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
CAP -X- _ I-Patient
when -X- _ O
influenza -X- _ O
is -X- _ O
suspected -X- _ O
or -X- _ O
documented -X- _ O
, -X- _ O
regardless -X- _ O
of -X- _ O
evidence -X- _ O
of -X- _ O
bacterial -X- _ O
co-infection. -X- _ O
Better -X- _ O
ways -X- _ O
to -X- _ O
diagnose -X- _ O
viral -X- _ O
CAP -X- _ O
and -X- _ O
to -X- _ O
integrate -X- _ O
detection -X- _ O
into -X- _ O
management -X- _ O
are -X- _ O
urgently -X- _ O
needed -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
better -X- _ O
treatment -X- _ O
options -X- _ O
for -X- _ O
non-influenza -X- _ O
respiratory -X- _ O
viral -X- _ O
infections -X- _ O
. -X- _ O

